The estimated Net Worth of Andrew Arno is at least 344 千$ dollars as of 11 April 2024. Mr. Arno owns over 33,898 units of Oncocyte stock worth over 214,067$ and over the last 13 years he sold OCX stock worth over 0$. In addition, he makes 130,341$ as Independent Director at Oncocyte.
Andrew has made over 10 trades of the Oncocyte stock since 2011, according to the Form 4 filled with the SEC. Most recently he bought 33,898 units of OCX stock worth 99,999$ on 11 April 2024.
The largest trade he's ever made was buying 250,000 units of Oncocyte stock on 23 December 2022 worth over 87,500$. On average, Andrew trades about 15,248 units every 100 days since 2011. As of 11 April 2024 he still owns at least 69,054 units of Oncocyte stock.
You can see the complete history of Mr. Arno stock trades at the bottom of the page.
Andrew Arno serves as Independent Director of the Company. He is currently Vice Chairman of “The Special Equities Group” at Bradley Woods, a privately held investment banking firm, after serving as a Vice Chairman at Chardan Capital Markets, LLC. From June 2013 until July 2015 Mr. Arno served as Managing Director of Emerging Growth Equities, an investment bank, and Vice President of Sabr, Inc., a family investment group. He was previously President of LOMUSA Limited, an investment banking firm. From 2009 to 2012, Mr. Arno served as Vice Chairman and Chief Marketing Officer of Unterberg Capital, LLC, an investment advisory firm that he co-founded. He was also Vice Chairman and Head of Equity Capital Markets of Merriman Capital LLC, an investment banking firm, and served on the board of the parent company, Merriman Holdings, Inc. Mr. Arno currently serves on the boards of directors of Smith Micro Software, Inc. and served as a director of Asterias Biotherapeutics, Inc. from August 2014 until it was acquired by Lineage Cell Therapeutics, Inc. in March 2019.
As the Independent Director of Oncocyte, the total compensation of Andrew Arno at Oncocyte is 130,341$. There are 6 executives at Oncocyte getting paid more, with Ronald Andrews having the highest compensation of 2,102,210$.
Andrew Arno is 60, he's been the Independent Director of Oncocyte since 2015. There are 5 older and 2 younger executives at Oncocyte. The oldest executive at Oncocyte Corporation is Dr. Michael D. West Ph.D., 68, who is the Scientific Advisor, Co-CEO of Biotime,Inc. & Pres of Biotime,Inc..
Andrew's mailing address filed with the SEC is C/O ONCOCYTE CORPORATION, 15 CUSHING, IRVINE, CA, 92618.
Over the last 9 years, insiders at Oncocyte have traded over 16,389,842$ worth of Oncocyte stock and bought 56,056,405 units worth 102,313,246$ . The most active insiders traders include Partners, L.P.Broadwood Cap...、Cell Therapeutics, Inc. Lin...、Partners, L.P.Bradsher Neal.... On average, Oncocyte executives and independent directors trade stock every 37 days with the average trade being worth of 3,382,106$. The most recent stock trade was executed by Josh Riggs on 11 April 2024, trading 3,390 units of OCX stock currently worth 10,001$.
oncocyte is focused on the discovery, development, and commercialization of non-invasive, liquid biopsy diagnostics to facilitate clinical decision making in the early detection of cancer. the company's pipeline is focused on molecular tests for areas of high unmet need - lung, breast, and bladder cancers - where the current standard of diagnostic care is often ambiguous, costly, and involves invasive surgical procedures. oncocyte's diagnostics are developed based on a proprietary set of biomarkers that have been shown to differentiate benign from malignant nodules or masses. for more information, visit www.oncocyte.com.
Oncocyte executives and other stock owners filed with the SEC include: